2 results
Approved WMORecruiting
To determine non inferiority of two doses of BI 10773 (10 mg/daily and 25 mg/daily) compared to placebo with respect to first occurrence of any of the adjudicated components of the primary composite Major Adverse Cardiovascular Event endpoint (…
Approved WMOCompleted
To test the first feasibility and safety of intratumoral 166-holmium microspheres implantation in pancreatic cancer in a controlled, open-surgery setting.